Accéder au contenu
Merck

DNA Methylation Regulates Alternative Polyadenylation via CTCF and the Cohesin Complex.

Molecular cell (2020-04-26)
Vishal Nanavaty, Elizabeth W Abrash, Changjin Hong, Sunho Park, Emily E Fink, Zhuangyue Li, Thomas J Sweet, Jeffrey M Bhasin, Srinidhi Singuri, Byron H Lee, Tae Hyun Hwang, Angela H Ting
RÉSUMÉ

Dysregulation of DNA methylation and mRNA alternative cleavage and polyadenylation (APA) are both prevalent in cancer and have been studied as independent processes. We discovered a DNA methylation-regulated APA mechanism when we compared genome-wide DNA methylation and polyadenylation site usage between DNA methylation-competent and DNA methylation-deficient cells. Here, we show that removal of DNA methylation enables CTCF binding and recruitment of the cohesin complex, which, in turn, form chromatin loops that promote proximal polyadenylation site usage. In this DNA demethylated context, either deletion of the CTCF binding site or depletion of RAD21 cohesin complex protein can recover distal polyadenylation site usage. Using data from The Cancer Genome Atlas, we authenticated the relationship between DNA methylation and mRNA polyadenylation isoform expression in vivo. This DNA methylation-regulated APA mechanism demonstrates how aberrant DNA methylation impacts transcriptome diversity and highlights the potential sequelae of global DNA methylation inhibition as a cancer treatment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
5-Aza-2′-deoxycytidine, ≥97%
Sigma-Aldrich
4-Thiouridine, ≥98%
Sigma-Aldrich
Indole-3-acetic acid sodium salt, BioReagent, suitable for plant cell culture, ≥98%
Sigma-Aldrich
3,3-Dimethylacryloyl chloride, 97%, contains 400 ppm phenothiazine as inhibitor
Supelco
Acide 3-indoleacétique, PESTANAL®, analytical standard
Sigma-Aldrich
Anti-DNMT1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution